IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IRulya Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$34.45+2.42 (+7.56%)
Close on Oct 19, 2026
- Market cap
- $211.28M
- P/E (TTM)
- –
- Dividend yield
- –
IRulya Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Market Cap | $35.04M | $166.30M |
| Enterprise Value | -$80.96M | $88.19M |
Income (trailing twelve months)
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$127.16M | -$21.40M |
| Net Income | -$92.48M | -$22.46M |
| EBITDA | -$127.00M | -$16.91M |
Returns
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -76.7% | -40.9% |
| Return on Capital Employed (ROCE) | -110.1% | -38.1% |
Balance sheet
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $116.00M | $61.43M |
| Total Debt | $0 | $118.52M |
| Net Cash (Debt) | $116.00M | $15.35M |
| Net Cash Per Share | $114.05 | $0.66 |
| Equity (Book Value) | -$35.32M | $49.09M |
| Book Value Per Share | -$34.73 | $1.37 |
| Tangible Book Value | -$35.32M | $23.52M |
| Working Capital | $114.91M | $76.81M |
Financial position
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 14.52 | 3.34 |
| Quick Ratio | 13.65 | 2.44 |
Cash flow (trailing twelve months)
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$46.92M | -$12.35M |
| Capital Expenditures | -$78.00K | -$1.08M |
| Free Cash Flow | -$47.00M | -$20.22M |
| FCF Per Share | -$46.21 | -$0.42 |
Efficiency
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.43M | -$703.34K |
| Employee Count | 38 | 74 |
Dividends and yields
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -263.9% | -23.3% |
| FCF Yield | -134.1% | -8.72% |
Shares
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,017,060 | 58,127,000 |
| Shares Change (YoY) | 97.3% | 10.9% |
| Shares Change (QoQ) | -92.6% | 0.54% |
| Shares Held by Institutions | 32.5% | 59.4% |
Taxes
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$2.16M | $79.87K |
Scores
| Measure | IRulya Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -6.56 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from IRulya Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.